Individuals living near golf courses, as well as those who reside in water service areas that include golf courses, are at ...

Job cuts at home-grown pharma companies like Arvinas and RallyBio and federal policies challenge CT biotech 'ecosystem' that ...

The advisory committee, which met after the agency rolled out new vaccine guidelines, said companies should tailor their ...

Migraine is recognized globally as the seventh most disabling condition across all diseases, accounting for approximately 2.9% of all years lived with disability (YLDs). It is also the top cause of ...

Juvenescence closes $76m first tranche of Series B-1 financing led by Abu Dhabi's M42 alongside strategic partnership Close of $76m Series B-1 tranche follows recent announcement of groundbreaking ...

In an effort to offset declining COVID-19 product sales, Pfizer embarked on an aggressive acquisition strategy, purchasing Seagen, Global Blood Therapeutics, and Biohaven. While the Seagen ...

Pharmaceutical stocks, including Pfizer (NYSE: PFE), have recently been scrutinized after President Trump’s executive order instructing drug manufacturers to reduce medicine prices to align with ...

Pfizer is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years.Shares are down 19% over the past ...

If it wins approval, troriluzole would represent Biohaven’s first greenlit product since it spun out from its migraine business following a $11.6bn acquisition from Pfizer back in 2022.

Pfizer has increased its dividend for 16 straight ... including migraine therapy Nurtec ODT (gained through its 2022 acquisition of Biohaven Pharmaceutical) and cancer drug Padcev (picked up ...

Pfizer (January 2025): Pfizer Inc. and its subsidiary Biohaven Pharmaceutical Holding Company Ltd. agreed to pay nearly $60 million to settle False Claims Act and Anti-Kickback Statute allegations.